Antidepressant Labeling Should Reflect Negative Pediatric Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
With study results for several drugs failing to show pediatric efficacy, an FDA advisory committee suggests revising a standard labeling statement that efficacy "has not been established" in children. The committee also recommends that labeling highlight the need for suicide monitoring.